Aging is malleable, at least in animal models. But to prove the efficacy of interventions aimed at extending healthspan and to test life-extending approaches in humans, longevity researchers first need to agree on the best measuring tools. With the power of ’omics, AI and large biobanks, improved biomarkers may be forthcoming. Companies and academic researchers are rallying forces, but how far have they gotten? Aging is malleable, at least in animal models. But to prove the efficacy of interventions aimed at extending healthspan and to test life-extending approaches in humans, longevity researchers first need to agree on the best measuring tools. With the power of ’omics, AI and large biobanks, improved biomarkers may be forthcoming. Companies and academic researchers are rallying forces, but how far have they gotten?